Long-Term Follow-Up of P-BCMA-101 for Multiple Myeloma

Recruiting in Palo Alto (17 mi)

+15 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Poseida Therapeutics, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

Eligibility Criteria

This trial is for individuals who have previously received P-BCMA-101 T cell treatment for multiple myeloma, either completing or discontinuing early from a Poseida sponsored study. Participants must consent to long-term follow-up.

Inclusion Criteria

You have already taken P-BCMA-101 as part of another study sponsored by Poseida and either finished or stopped early.

Subject has provided informed consent.

Exclusion Criteria

N/A

Participant Groups

The study monitors the safety and effectiveness of P-BCMA-101 T cells over 15 years post-treatment. It evaluates the risk of delayed side effects, ongoing benefits, and tracks levels of these specialized T cells in subjects.

1Treatment groups

Experimental Treatment

Group I: P-BCMA-101 treatedExperimental Treatment1 Intervention

Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.